The global Insulin Glargine Market is estimated to be valued at US$ 6178.14 Mn in 2023 and is expected to exhibit a CAGR of 6.28% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Insulin Glargine is a long-acting analog of human insulin used to treat diabetes. It works by helping the body regulate glucose levels in the blood. Biosimilar versions of Insulin Glargine offer equivalent therapeutic options at a lower cost and help increase the accessibility of treatment.
Market key trends:
One of the key trends in the Insulin Glargine Market is the increasing approval and launch of more affordable biosimilar versions. Major players are investing in development of biosimilar versions to gain market share. For instance, in 2023, Mylan received approval for its proposed biosimilar insulin glargine and plans to launch it to provide a more affordable treatment option. This is expected to increase the demand and drive the growth of the overall Insulin Glargine Market during the forecast period.
Segment Analysis:
The global insulin glargine market is segmented on the basis of distribution channel and application. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment holds the highest market share as insulin glargine is mainly administered to patients by physicians and pharmacists in hospitals. Based on application, the market is segmented into diabetes, oncology, and others. The diabetes segment accounts for the largest share as insulin glargine is one of the preferred long-acting insulin therapies for the treatment of type 1 and type 2 diabetes.
Key Takeaways:
The Global Insulin Glargine Market Size is expected to witness high growth, exhibiting a CAGR of 6.28% over the forecast period, due to increasing prevalence of diabetes around the world.
Regional analysis:
North America dominates the global insulin glargine market and is expected to continue its dominance over the forecast period. This is attributed to increasing healthcare expenditure and growing diabetic population in the region. Asia Pacific is expected to be the fastest growing market for insulin glargine owing to rising awareness about diabetes treatment and improving access to healthcare in developing countries of the region.
Key players
Key players operating in the insulin glargine market are Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS. Eli Lilly is a leader in the insulin glargine market with its blockbuster product – Lantus - a long-acting human insulin analog. Biocon also has a significant presence with its product – Semglee, approved as a biosimilar to Lantus in several countries including U.S. and Europe.
Explorer more information on this topic, Please visit -
https://www.insightprobing.com/insulin-glargine-market-share-and-demand-analysis/
